Back to Newsroom

ProMIS Neurosciences Designates PMN330 as Third, Validated Lead Product for Development in Alzheimer’s Disease

TORONTO, Ontario and Cambridge, Massachusetts – Sept. 13, 2017 – ProMIS Neurosciences, Inc., a company focused on discovery and development of precision treatments for neurodegenerative diseases, today announced it has designated PMN330, a monoclonal antibody (mAb) targeting toxic prion-like forms of amyloid-beta oligomers (AβO), as its third lead product for development in Alzheimer’s disease (AD).